Gastric cancer her2(1+) is a negative test result, indicating that the patient’s overall prognosis is good and generally does not require treatment with targeted drugs.
her2 is an oncogene, a proto-oncogene located on chromosome 17q21, which can stimulate cell growth and differentiation. Gastric cancer her2(1+) is found when immunohistochemistry examination is performed and the patient is found to be negative for human epidermal growth factor receptor 2. Negative results generally indicate that the patient’s prognosis is better than that of patients with positive results.
Gastric cancer her2(1+) patients are generally not suitable for treatment with targeted drugs, but can be treated by surgery, chemotherapy, radiation therapy, etc. If patients are treated in time, the prognosis is usually better.
Gastric cancer her2(1+) patients should undergo timely treatment and follow the doctor’s instructions to go to the hospital for regular follow-up to avoid adverse effects.